Institutional review boards (IRBs) are ethics review committees that ensure human research subjects’ rights are protected, as well as the rights of the patients who ultimately benefit from the research. Operating under US federal regulations, state laws, and institutional policies, the IRB has the authority to approve, require modification to, and disapprove research. IRBs are an important part of regulatory efforts and their approval is required for all human research. Here’s a quick overview of IRBs and the expectations for working with them.
Approximately 80 percent of clinical research sites polled in a recent Complion, Inc.-sponsored survey said the costs and burden associated with administrative tasks for a single study has increased over the past two years, continuing a five-year upward trend.
Because research study sponsors are continually seeking efficiencies, and all stakeholders in studies have an interest in minimizing the time required of, and the potential risk to, volunteers who participate in studies, there will be a decrease in the number of single drug studies in the future. That is the observation of John Neal, CEO of PCRS Network. In the final post of this four-part series, we explore the evolution of clinical research and the opportunity for collaboration among multiple sponsors based on Neal’s insights.
Inefficient and ineffective. That’s how John Neal, CEO of PCRS Network, sums up his frank assessment of the current state of the clinical research site selection process. In the third post of this four-part series, we explore the evolution of clinical research and its impact on the site selection process based on insights presented by Neal.
We live in an age when we are surrounded by technologies that are improving the speed and efficiency with which we can gather information, and the depth and breadth of that information. In this four-part series, we explore the evolution of clinical research based on insights presented by John Neal, CEO of PCRS Network. In this second post, Neal takes a look at the area of data collection.
No human endeavor is immune to change, and that is certainly true for clinical research. In this four-part series, we explore the variety of factors driving the evolution of clinical research based on insights presented by John Neal, CEO of PCRS Network.